Literatur
- 1
Barnes P J, Woolcock A J.
Difficult asthma.
Eur Respir J.
1998;
12
1209-1218
- 2
Barnes P J, Jonsson B, Klim J B.
The costs of asthma.
Eur Respir J.
1996;
9
636-642
- 3
Chung K F. et al .
For the ERS Task Force on Difficult/Therapy - Resistant Asthma Difficult/therapy -
resistant Asthma.
Eur Respir J.
1999;
13
1198-1208
- 4
Busse W W, Banks-Schlegel S, Wenzel S E.
Pathophysiology of severe asthma.
J Allergy Clin Immunol.
2000;
106
1033-1042
- 5
ten Brinke A, van Dissel J T, Sterk P J, Zwinderman A H, Rabe K F, Bel E H.
Persistent Airflow Limitation in Adult-onset Nonatopic Asthma is associated with Serological
Evidence of Chlamydia Pneumonieae Infection.
J Allergy Clin Immuol.
2001;
107
449-454
- 6
ten Brinke A, Zwinderman A H, Sterk P J, Rabe K F, Bel E H.
Factors associated with Airflow Limitation in Severe Asthma.
Am J Respir Crit Care Med.
2001;
164
744-748
- 7
ten Brinke A, de Lange C, Zwinderman A H, Rabe K F, Sterk P J, Bel E H.
Sputum Induction in Severe Asthma by a Standardized Protocol. Predictors of Excessive
Bronchoconstriction.
Am J Respir Crit Care Med.
2001;
164
749-753
- 8
Anonymous .
Guidelines for the diagnosis and management of asthma.
Expert panel report 2. Bethesda (MD); NIH.
1997;
Publication No.
97-4051
- 9
Wenzel S E, Fahy J V, Irvin C, Peters S P, Spector S, Szefler S.
Proceedings of the ATS Workshop on Refractory Asthma: current understanding, recommendations
and unanswered questions.
Am J Respir Crit Care Med.
2000;
162
2341-2351
- 10
Woolcock A J.
Steroid resistant asthma: What is the clinical definition?.
Eur J Respir Dis.
1993;
6
743-747
- 11
Thomas P S, Geddes D M, Barnes P J.
Pseudo-steroid resistant asthma.
Thorax.
1999;
54
352-356
- 12
Wenzel S E, Schwartz L B, Langmack E L, Halliday J L, Trudeau J B, Gibbs R L. et al
.
Evidence that severe asthma can be divided pathologically in two inflammatory subtypes
with distinct physiologic and clinical characteristics.
Am J Respir Crit Care Med.
1999;
160
1001-1008
- 13
Ayres J G, Miles J F, Barnes P J.
Brittle asthma.
Thorax.
1998;
53
315-321
- 14
Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, Bousquet J,
Chanez P.
Rhinosinusitis in severe asthma.
J Allergy Clin Immunol.
2001;
107 (1)
73-80
- 15
Wiesch D G, Meyers D A, Bleecker E R.
Genetics of asthma.
J Allergy Clin Immunol.
1999;
104
895-901
- 16
Sporik R, Holgate S T, Platts-Mills T AE, Cogswell J J.
Exposure to house-dust mite allergene (Der p.I.) and the development of asthma in
childhood.
N Engl J Med.
1990;
323
502-507
- 17
Squillace S P, Sporik R B, Rakes G, Couture N, Lawrence A, Merriam S. et al .
Sensitization to dust mites as a dominant risk factor for asthma among adolescents
living in central Virginia. Multiple regression analysis of a population - based study.
Am J Respir Crit Care Med.
1997;
156
1760-1764
- 18
Neukirch C, Henry C, Leynaert B, Liard R, Bousquet J, Neukirch F.
Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based
study.
J Allergy Clin Immunol.
1999;
103
709-711
- 19
Grootendorst D C, ten Brinke A, Sterk P J, Rabe K F, Bel E H.
Different allergic profile in patients with early and late onset severe asthma.
Am J Respir Crit Care Med.
2000;
160
A323
- 20
Martinez F D, Wright A L, Taussig L M, Holberg C J, Halonen M, Morgan W J. et al .
Asthma and wheezing in the first six years of life.
N Engl J Med.
1995;
332
133-138
- 21
Stein R T, Sherrill D, Morgan W J, Holberg C J, Halonen M, Taussig L M. et al .
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13
years.
Lancet.
1999;
354
541-545
- 22
Folkerts G, Busse W W, Nijkamp F P, Sorkness R, Gern J E.
Virus - induced airway hyperresponsiveness and asthma.
Am J Respir Crit Care Med.
1998;
157
1708-1720
- 23
Johnston S L, Pattemore P K, Sanderson G, Smith S, Lampe F, Josephs L K. et al .
Community study of role of viral infections in exacerbations of asthma in 9 - 11-year
old children.
BMJ.
1995;
310
1225-1228
- 24
Johnston S L, Pattemore P K, Sanderson G, Smith S, Campbell M J, Josephs L K. et al
.
The relationship between upper respiratory infections and hospital admissions for
asthma: a time-trend analysis.
Am J Respir Crit Care Med.
1996;
154
654-660
- 25
Hogg J C.
Childhood viral infection and the pathogenesis of asthma and chronic obstructive lung
disease.
Am J Respir Crit Care Med.
1999;
160
S26-28
- 26
Kraft M, Cassell G H, Henson J E, Watson H, Wiliamson J, Marmion B P. et al .
Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma.
Am J Respir Crit Care Med.
1998;
158
998-1001
- 27
Matsuse T, Hayashi S, Kuwano K, Keunecke H, Jefferies W A, Hogg J C.
Latent adenoviral infection in the pathogenesis of chronic airways obstruction.
Am Rev Respir Dis.
1992;
146
177-184
- 28
Hahn D L.
Chlamydia pneumoniae, asthma, and COPD: what is the evidence?.
Ann Allergy Asthma Immunol.
1999;
83
271-292
- 29
ten Brinke A, van Dissel J T, Sterk P J, Zwinderman A H, Rabe K F, Bel E H.
Persistent airflow limitation in adult - onset nonatopic asthma in associated with
serologic evidence of Chlamydia pneumoniae infection.
J Allergy Clin Immunol.
2001;
107
449-454
- 30
Sher E R, Leung D YM, Surs W, Kam J C, Zieg G, Kamada A K. et al .
Steroid - resistant asthma - cellular mechanisms contributing to inadequate response
to Glucocorticoid therapy.
J Clin Invest.
1994;
93
33-39
- 31
Leung D YM, Hamid Q, Vottero A, Szefler S J, Surs W, Minshall E. et al .
Association of glucocorticoid insensitivity with increased expression of glucocorticoid
receptor beta.
J Exp Med.
1997;
186
1567-1574
- 32
Sousa A R, Lane S J, Cidlowski J A, Staynov D Z, Lee T H.
Glucocorticoid resistence in Asthma is associated with elevated in vivo expression
of the Glucocorticoid receptor beta - isoform.
J Allergy Clin Immunol.
2000;
105
943-950
- 33
Oehling A G, Akdis C A, Schapowal A, Blaser K, Schmitz M, Simon H-U.
Suppression of the immune system by oral glococorticoid therapy in bronchial asthma.
Allergy.
1997;
52
144-154
- 34
Gratzl S, Palca A, Schmitz M, Simon H U.
Treatment with IFN-alpha in corticosteroid-unresponsive asthma.
J Allergy Clin Immunol.
2000;
105
1035-1036
- 35
Menz G, Willer G, Crameri R.
Die allergische bronchopulmonale Aspergillose (ABPA).
Pneumologie.
2000;
54
375-384
- 36
Grootendorst D C, Dahlén S-E, van den Bos J W, Duiverman E J, Veselic-Charvat M, Vrijlandt E JLE,
O'Sullivan S, Kumlin M, Sterk P J, Roldaan A C.
Benefits of high altitude allergen avoidance in atopic adolescents with moderate to
severe asthma, over an above treatment with high dose inhaled steroids.
Clinical and Experimental Allergy.
2000;
31
400-408
- 37
Gillissen A, Schäfer H, Tasci S, Ewig S.
Alternativen zur Standardtherapie des Asthma bronchiale.
Dtsch Med Wschr.
2000;
125
1575-1579
- 38
Virchow Jr C, Prasse A, Naya I, Summerton L, Harris A. and the Zafirlukast Study Group
.
Zafirlukast Improves Asthma Control in Patients receiving High-Dose Inhaled Corticosteroids.
Am J Respir Crit Care Med.
2000;
162
578-585
- 39
Schmidt D T, Rabe K F.
Reliable and modern therapy of allergic bronchial asthma.
Der Internist.
2000;
41 (12)
1391-1398
- 40
Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Related Articles
Gupta N, Della Cioppa G.
The anti-IgE antibody omalizumab reduced exacerbations and steroid requierement in
allergic asthmatic.
Eur Respir J.
2001;
18 (2)
254-261
- 41
Busse W, Corren J, Lanier B Q, McAlary M, Fowler-Taylor A, Cioppa G D, von As A, Gupta N.
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment
of severe allergic asthma.
J Allergy Clin Immunol.
2001;
108 (2)
184-190
PD Dr. med. G. Menz
Hochgebirgsklinik Davos-Wolfgang
7265 Davos-Wolfgang
Schweiz
Email: guenter.menz@hgk.ch
